ClinicalTrials.gg
CompletedNCT07070544Updated Nov 20, 2026

Effect of Electromagnetic Field Therapy and Customized Foot Insole on Peripheral Circulation and Ankle-Brachial Pressure Index in Patients With Diabetic Foot Ulcer

An interventional study of Electromagnetic Field Therapy: • Frequency: 50 Hz • Intensity: 5-30 mT • Duration: 30 minutes/session • Frequency: 3 sessions/week for 8 weeks Customized Foot Insoles: • Individually tailored based on in Diabetes Mellitus and Diabetic Foot Ulcer, sponsored by South Valley University. Completed at 1 site in Egypt. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Primary conditionDiabetic FootRegistry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetic Foot
Why
  1. The study's listed conditions name Diabetic Foot, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by South Valley University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now CompletedFirst site in Egypt+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Diabetic Foot with a site in Egypt — 7 open to participants now, 8 under way, none of them phase 3. Diabetic Foot · Egypt.

Enrollment
7th of 26
79 · median 49
Started
2025
with 5 others
No phase
21 of 30
6 open now
Registered
24th of 30
by date

Among the 30 studies in Diabetic Foot with a site in Egypt, this one is the 7th largest by enrollment of the 26 interventional ones that give a count, is one of 6 that started in 2025, is one of 21 with no phase, and was the 24th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

7 of the 30 studies in Diabetic Foot with a site in Egypt are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Diabetic Foot with a site in Egypt, or all of them as a file.
02

Study summary

Diabetic foot ulcers (DFUs) are a significant complication of diabetes mellitus, associated with poor peripheral circulation, neuropathy, and increased risk of lower-limb amputation. Optimizing peripheral blood flow is critical in the prevention and management of DFUs. Traditional offloading strategies, such as customized foot insoles, have demonstrated efficacy in reducing plantar pressure and promoting ulcer healing.

Electromagnetic field (EMF) therapy is a non-invasive modality that has shown potential in enhancing microcirculation, promoting angiogenesis, and modulating inflammatory processes. Preliminary studies have suggested that EMF may improve peripheral circulation and tissue oxygenation in diabetic patients.

This study aims to investigate the combined effect of EMF therapy and customized foot insoles on peripheral circulation and Ankle-Brachial Pressure Index (ABPI) in patients with diabetic foot ulcers, hypothesizing that this integrated approach may yield superior outcomes compared to standard care.

Read the detailed description

2. Objectives

Primary Objective:

  • To evaluate the effect of EMF therapy combined with customized foot insoles on peripheral circulation in patients with diabetic foot ulcers.

Secondary Objective:

  • To assess changes in Ankle-Brachial Pressure Index (ABPI) following intervention.
  • To compare the ulcer healing rates and pain levels between intervention and control groups.

    3. Research Questions

    1. Does the combination of EMF therapy and customized foot insoles improve peripheral circulation in patients with diabetic foot ulcers?
    2. Is there a significant improvement in ABPI in the intervention group compared to control?
    3. What is the effect of the intervention on ulcer healing rates and pain reduction?

      ________________________________________

    4. Hypotheses
  • H1: EMF therapy combined with customized foot insoles significantly improves peripheral circulation compared to standard care.
  • H2: EMF therapy combined with customized foot insoles significantly improves ABPI in patients with diabetic foot ulcers.
03

Conditions studied

  • Diabetes Mellitus
  • Diabetic Foot Ulcer

Browse trials for

Keywords

  • Effect of Electromagnetic Field Therapy
  • Customized Foot Insole
  • Peripheral Circulation
  • Ankle-Brachial Pressure Index
04

In context

Diabetic Foot Reclassified

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

This study's enrollment of 79 is above the median of 60 across 849 interventional studies indexed under Diabetic Foot.

Browse Diabetic Foot studies →

Lead sponsor

South Valley University is the lead sponsor of 154 studies on the registry; 38 are open to participants now.

Compared within Diabetic Foot, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Diagnosed with Type 2 Diabetes Mellitus.

      • Presence of unilateral or bilateral diabetic foot ulcer.
      • ABPI between 0.6 - 1.0 (mild to moderate arterial insufficiency).

Exclusion criteria

Exclusion Criteria:

    • Severe peripheral arterial disease (ABPI \<0.5).

      • Active infection requiring hospitalization.
      • History of amputation.
      • Cardiac pacemaker or to EMF therapy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
79 participants (actual)

Study arms

  • Active comparator
    The study Group

    Electromagnetic Field Therapy: * Frequency: 50 Hz * Intensity: 5-30 mT * Duration: 30 minutes/session * Frequency: 3 sessions/week for 8 weeks Customized Foot Insoles: * Individually tailored based on foot pressure mapping and deformity. * Designed to offload pressure points and support foot arches. Standard Care: • Wound care, glycemic control, and patient education as per institutional protocol.

    Device: Electromagnetic Field Therapy: • Frequency: 50 Hz • Intensity: 5-30 mT • Duration: 30 minutes/session • Frequency: 3 sessions/week for 8 weeks Customized Foot Insoles: • Individually tailored based on

  • Placebo comparator
    The control group

    Standard Care: • Wound care, glycemic control, and patient education as per institutional protocol.

    Device: Electromagnetic Field Therapy: • Frequency: 50 Hz • Intensity: 5-30 mT • Duration: 30 minutes/session • Frequency: 3 sessions/week for 8 weeks Customized Foot Insoles: • Individually tailored based on

Interventions

  • DeviceElectromagnetic Field Therapy: • Frequency: 50 Hz • Intensity: 5-30 mT • Duration: 30 minutes/session • Frequency: 3 sessions/week for 8 weeks Customized Foot Insoles: • Individually tailored based on

    Electromagnetic Field Therapy: * Frequency: 50 Hz * Intensity: 5-30 mT * Duration: 30 minutes/session * Frequency: 3 sessions/week for 8 weeks Customized Foot Insoles: * Individually tailored based on foot pressure mapping and deformity. * Designed to offload pressure points and support foot arches. Standard Care: • Wound care, glycemic control, and patient education as per institutional protocol.

07

What researchers measure

Primary outcomes

  1. Blood flow

    Primary Outcome: • Peripheral Circulation: Assessed by Laser Doppler Flowmetry and/or skin perfusion pressure (SPP).

    Time frame: Measurement Timeline: • Minimum value (Baseline)(Week 0) • Mid-intervention (Week 4) • Maximum value (Post-intervention) (Week 8) • Follow-up (Week 12)

Secondary outcomes

  1. • Ankle-Brachial Pressure Index (ABPI)

    • Ankle-Brachial Pressure Index (ABPI): Measured using handheld Doppler.

    Time frame: Measurement Timeline: • Minimum value (Baseline) (Week 0) • Mid-intervention (Week 4) • Maximum value (Post-intervention) (Week 8) • Follow-up (Week 12)

  2. • Ulcer Healing Rate

    • Ulcer Healing Rate: Monitored through ulcer size reduction (planimetric tracing and digital photography).

    Time frame: Measurement Timeline: • Minimum value (Baseline) (Week 0) • Mid-intervention (Week 4) • Maximum value (Post-intervention) (Week 8) • Follow-up (Week 12)

  3. • Pain Level:

    • Pain Level: Measured using the Visual Analog Scale (VAS).

    Time frame: Measurement Timeline: • Minimum value (Baseline) (Week 0) • Mid-intervention (Week 4) • Maximum value (Post-intervention) (Week 8) • Follow-up (Week 12)

08

Study locations

1 site
  • Hany elgohary
    Qina, Egypt
09

References and documents

Publications

  • Burhan A, Arofiati F, Da Silva VA, Sebayang SM. Effect of Ankle Brachial Index (ABI) and Compression Therapy on Diabetic Foot Ulcer Healing. Curr Diabetes Rev. 2024;20(1):e310323215277. doi: 10.2174/1573399819666230331083420. PubMed 37005544 ↗

Related links

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Jan 2026, 5 months.

Of 243 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's 5 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Aug 2025 → Jul 2025 and primary completion Dec 2025 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2025
First posted
Jul 17, 2025
StartActual
Jul 10, 2025was Aug 2025
Primary completionActual
Jan 7, 2026was Dec 2025
CompletionActual
Jan 10, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 20, 2026
Sites
1 site added — first site in Egypt
Show site
  • Hany elgohary · Qina, Egypt
Nov 20, 2026
Start date
Aug 1, 2025→Jul 10, 2025 (actual)
Nov 20, 2026
Primary completion
Dec 1, 2025→Jan 7, 2026 (actual)
Nov 20, 2026
Study completion
Jan 1, 2026→Jan 10, 2026 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Completed
    1 site added — first site in Egypt
    Show site
    • Hany elgohary · Qina, Egypt
    Start date Aug 1, 2025→Jul 10, 2025 (now actual)
    Primary completion Dec 1, 2025→Jan 7, 2026 (now actual)
    Study completion Jan 1, 2026→Jan 10, 2026 (now actual)
    + 6 other changes: identifiers, verification date, responsible party, oversight details, contact details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07070544
Collaborators
Jerash Private University
Responsible party
Ibrahim Abuzaid (Ibrahim ismail Abuzaid, South Valley University) — Principal investigator
First posted
Jul 17, 2025
Start date
Jul 10, 2025
Primary completion
Jan 7, 2026
Completion
Jan 10, 2026
Last update
Nov 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion